Endocrine Surgeons Discusses Thyroid, Parathyroid, and Adrenal Care
Endocrine surgeons primarily focus on the thyroid, parathyroid, and adrenal glands. For the thyroid, their work often ...
Zacks.com on MSN5d
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.
Medscape18h
‘Game Changer’ Approved for Congenital Adrenal Hyperplasia
The US Food and Drug Administration has approved crinecerfont for treating congenital CAH in combination with glucocorticoids ...
Medpage Today on MSN1d
FDA Approves First Drug for Classic Congenital Adrenal Hyperplasia in 70 Years
Crinecerfont is the first new treatment in 70 years for classic CAH and the only one that directly reduces excess ...
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel ...
Yahoo Finance4d
FDA Approves New Treatment for Congenital Adrenal Hyperplasia
SILVER SPRING, Md., Dec. 13, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control ...
clinicaladvisor.com1d
Crenessity Approved for Classic Congenital Adrenal Hyperplasia
The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.
Morningstar4d
FDA Approves New Treatment for Congenital Adrenal Hyperplasia
"Today's approval provides an important advance for patients with classic congenital adrenal hyperplasia and highlights the FDA's continued commitment to advancing effective and safe treatments ...
Yahoo Finance4d
FDA Approves New Treatment for Congenital Adrenal Hyperplasia
"Today's approval provides an important advance for patients with classic congenital adrenal hyperplasia and highlights the FDA's continued commitment to advancing effective and safe treatments for ...